EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Real‐world use of continuous glucose monitoring in people with type 2 diabetes and chronic kidney disease or on dialysis

Patrick McGown, Nikoleta Papanikolaou, Jasmine El-Taraboulsi, Clemency Britton, Javeria Iqtidar, Khuram Chaudhry, Shiyan Ng, Kishan Jethwa, Jagvi Patel, Jo Reed, Monika Reddy, Lalantha Leelarathna und 3 weitere

Diabetic Medicine · 2026

DOI: 10.1111/dme.70174 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Patrick McGown und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Imperial College London NHS Trust, London, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Blood Glucose Self-Monitoring, Blood Glucose. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Continuous glucose monitoring (CGM) has become the standard of care for people with type 1 diabetes (T1D) and some people with type 2 diabetes (T2D). However, there is a lack of data regarding CGM use in people with T2D and chronic kidney disease (CKD), who are at increased risk of hypoglycaemia. We assess the use of CGM and glucose outcomes in this cohort.

Methods

Retrospective, observational analysis of adults on CGM attending a tertiary diabetes renal clinic between January 2023 and September 2024. People with T2D on multiple daily insulin injections (defined as 2 or more insulin injections per day) and CKD stage 3–5 (eGFR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicBlood Glucose Self-MonitoringBlood GlucoseRenal DialysisDiabetic NephropathiesHumansFemaleMiddle AgedMaleRetrospective StudiesAgedGlycated HemoglobinHypoglycemic AgentsInsulinHypoglycemiaContinuous Glucose Monitoring

Stichwörter der Autor:innen

chronic kidney diseasecontinuous glucose monitoringhypoglycaemiatype 2 diabetes

Substanzen

Blood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Imperial College London NHS Trust, London, UK.
  • Department of Renal Medicine, Imperial College London NHS Trust, London, UK.
  • Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.

ORCID-Profile: Parizad Avari

Zitieren

APA

McGown, P., Papanikolaou, N., El-Taraboulsi, J., Britton, C., Iqtidar, J., Chaudhry, K., Ng, S., Jethwa, K., Patel, J., Reed, J., Reddy, M., Leelarathna, L., Frankel, A. H., Uduku, C., & Avari, P. (2026). Real‐world use of continuous glucose monitoring in people with type 2 diabetes and chronic kidney disease or on dialysis. Diabetic Medicine. https://doi.org/10.1111/dme.70174

Vancouver

McGown P, Papanikolaou N, El-Taraboulsi J, Britton C, Iqtidar J, Chaudhry K, et al. Real‐world use of continuous glucose monitoring in people with type 2 diabetes and chronic kidney disease or on dialysis. Diabetic Medicine. 2026. doi:10.1111/dme.70174

BibTeX
@article{McGown2026,
  author = {McGown, Patrick and Papanikolaou, Nikoleta and El-Taraboulsi, Jasmine and Britton, Clemency and Iqtidar, Javeria and Chaudhry, Khuram and Ng, Shiyan and Jethwa, Kishan and Patel, Jagvi and Reed, Jo and Reddy, Monika and Leelarathna, Lalantha and Frankel, Andrew H and Uduku, Chukwuma and Avari, Parizad},
  title = {Real‐world use of continuous glucose monitoring in people with type 2 diabetes and chronic kidney disease or on dialysis},
  journal = {Diabetic Medicine},
  year = {2026},
  doi = {10.1111/dme.70174}
}
Kostenlos starten →